Pioneering Past Informs Future as Budd Bioworks Unveils 300,000 sq. ft. cGMP BioManufacturing Space in Philadelphia

Published on :

After Decades of Dormancy, Philadelphia’s Powerhouse Budd Plant Presses Ahead as a New Biomanufacturing Center
PHILADELPHIA, PA   July 23, 2021 – A new future is forming around an iconic symbol of Philadelphia’s manufacturing past. The Plymouth Group, in partnership with Centerbridge Partners, L.P., is officially underway on an ambitious biomanufacturing redevelopment plan that puts the life changing therapies developed in Philadelphia’s “Cellicon Valley” on the production line. Spaces will be ready for tenant construction as soon as Q4 of 2021, positioning Philadelphia to meet the swelling demand for cGMP manufacturing nationwide.
The new development will be known as the Budd Campus with the 450,000 square foot Budd Bioworks representing Phase 1 of the project, a life sciences anchor to a 2.4 million square foot adaptive reuse plan that encompasses 6 buildings on over 25 acres in the middle of a major metropolitan area.
Budd Bioworks will comprise 300,000 square feet of cGMP drug manufacturing space along with 150,000 square feet of lab and office space. Residences, restaurants, retail and art activations are planned for subsequent phases within the greater Budd Campus. 
Sitting directly between Philadelphia’s Center City and its suburbs, the former Budd Company Hunting Park Plant holds a significant…

Regional Collaborations Emerge to Address the Biomanufacturing Workforce Crisis

Published on :

We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.

Maryland Showcases Life Sciences Ecosystem at BIODigital 2021

Published on :

When the Biotechnology Innovation Organization (BIO) convenes its annual trade show this month, Maryland’s life sciences ecosystem, which played a significant role in combating the global COVID-19 pandemic, will be on full display.

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges
Published on :

The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.

Biohealth Industry Day Highlights Partnerships and Pathways for Early-Career Professionals

Published on :

While the pandemic has forced many industries to downsize, biotech companies have had the opportunity — or sometimes the obligation — to ramp up. Just take a look at Catalent Pharma Solutions, the Baltimore-based contract manufacturer. The company has hired over 500 new employees since last March, said Talent Acquisition Specialist Charle’ Lamb during a panel at the Biohealth Industry Day.

Philadelphia’s Talent Pipeline Collaborative Readies Region For Cell And Gene Therapy Job Growth –

Published on :

The following op-ed, originally posted on CellandGene.com, was written by CEO Council Executive Director Claire Greenwood and Patricia Day, Manager, Leadership Engagement, Chamber of Commerce for Greater Philadelphia.  On the heels of a 2020 study predicting substantial job growth in the cell and gene therapy sector in Greater Philadelphia, industry leaders in our